CompletedNot Applicable

MAGNOLIA: Extension Study of Patients With Non-infectious Uveitis Who Participated in CLS1001-301

United States33 participantsStarted 2017-12-13

Plain-language summary

This study is a non-interventional, observational extension of the Parent study, CLS1001-301 (NCT02595398). The purpose of this study is to characterize the continued clinical benefit(s) regarding safety and efficacy of suprachoroidally administered CLS-TA, triamcinolone acetonide injectable suspension, for the treatment of macular edema associated with non-infectious uveitis.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Enrolled in the Parent study, CLS1001-301, through Visit 8/Month 6 * Willing and able to provide written informed consent prior to any study procedures; willing to comply with the instructions and attend all scheduled study visits Exclusion Criteria: * Received additional therapy for the treatment of uveitis or prohibited medication * Require additional therapy for the treatment of uveitis or prohibited medication at the time of the Crossover visit

What they're measuring

Time to Additional Therapy for Uveitis

Timeframe: 6 months following completion of the Parent study CLS1001-301 (NCT02595398), for a total of up to 1 year

Trial details

NCT IDNCT02952001

SponsorClearside Biomedical, Inc.

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2018-05-22

Results submitted2021-04-14

View on ClinicalTrials.gov More Uveitis trials